{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:23Z","timestamp":1760298083968},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1007\/bf03040747","type":"journal-article","created":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T08:19:00Z","timestamp":1242029940000},"page":"112-118","source":"Crossref","is-referenced-by-count":15,"title":["Arzneimittelwechselwirkungen mit Antiepileptika"],"prefix":"10.1007","volume":"116","author":[{"given":"Klaus","family":"Turnheim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03040747_CR1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0140-6736(74)90593-5","volume":"i","author":"D Janz","year":"1974","unstructured":"Janz D, Schmidt D (1974) Anti-epileptic drugs and failure of oral contraceptives. Lancet i: 1113","journal-title":"Lancet"},{"key":"BF03040747_CR2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(74)91929-1","volume":"ii","author":"H Laengner","year":"1974","unstructured":"Laengner H, Detering K (1974) Ant-epileptic drugs and failure of oral contraceptives. Lancet ii: 600","journal-title":"Lancet"},{"key":"BF03040747_CR3","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2165\/00003495-197612060-00003","volume":"12","author":"E Hempel","year":"1976","unstructured":"Hempel E, Klinger W (1976) Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications. Drugs 12: 442\u2013448","journal-title":"Drugs"},{"key":"BF03040747_CR4","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.1979.03290440024021","volume":"241","author":"JR Lewis","year":"1979","unstructured":"Lewis JR (1979) Oral contraceptive and antiepileptic drug interaction resulting in contraceptive failure. J Am Med Assoc 241: 2743","journal-title":"J Am Med Assoc"},{"key":"BF03040747_CR5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2165\/00003088-200241080-00002","volume":"41","author":"JW McAuley","year":"2002","unstructured":"McAuley JW, Anderson GD (2002) Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet 41: 559\u2013579","journal-title":"Clin Pharmacokinet"},{"key":"BF03040747_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00007691-200202000-00016","volume":"24","author":"H Hachad","year":"2002","unstructured":"Hachad H, Ragueneau-Majlessi I, Levy RH (2002) New aniepileptic drugs: review on drug interactions. Ther Drug Monit 24: 91\u2013103","journal-title":"Ther Drug Monit"},{"key":"BF03040747_CR7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","volume":"43","author":"PN Patsalos","year":"2002","unstructured":"Patsalos PN, Fr\u00f6scher W, Pisani F, van Rijn CM (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43: 365\u2013385","journal-title":"Epilepsia"},{"key":"BF03040747_CR8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0531-5565(03)00133-5","volume":"38","author":"K Turnheim","year":"2003","unstructured":"Turnheim K (2003) When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontology 38: 843\u2013853","journal-title":"Exp Gerontology"},{"key":"BF03040747_CR9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archfami.3.7.589","volume":"7","author":"JC Cloyd","year":"1994","unstructured":"Cloyd JC, Lackner TE, Leppik IE (1994) Antiepileptics in the elderly: pharmacoepidemiology and pharmacokinetics. Arch Family Med 7: 589\u2013598","journal-title":"Arch Family Med"},{"key":"BF03040747_CR10","first-page":"1122","volume-title":"Basic and clinical pharmacology","author":"PD Hansten","year":"2001","unstructured":"Hansten PD (2001) Important drug interactions and their mechanisms. In: Katzung BG (ed) Basic and clinical pharmacology. 8th edn. Lange Medical Books\/McGraw-Hill, New York, pp 1122\u20131133","edition":"8th edn."},{"key":"BF03040747_CR11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s001080050515","volume":"41","author":"A Paneitz","year":"2000","unstructured":"Paneitz A, Messner K, Kr\u00f6mer HK (2000) Arzneimittelinteraktionen: neue Mechanismen und klinische Relevanz. Internist 41: 338\u2013343","journal-title":"Internist"},{"key":"BF03040747_CR12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00002512-199812060-00006","volume":"12","author":"KM Seymour","year":"1998","unstructured":"Seymour KM, Routledge PA (1998) Important drug interactions in the elderly. Drugs Aging 12: 485\u2013494","journal-title":"Drugs Aging"},{"key":"BF03040747_CR13","first-page":"126","volume-title":"Grundlagen der Geriatrie","author":"K Turnheim","year":"2002","unstructured":"Turnheim K (2002) Arzneimittelinteraktionen in der Geriatrie. In: B\u00f6hmer F, Rhomberg HP, Weber E (Hrsg) Grundlagen der Geriatrie. Verlagshaus der \u00c4rzte GmbH, Wien, S 126\u2013134"},{"key":"BF03040747_CR14","volume-title":"Drug interactions: a source book of adverse interactions, their mechanisms, clinical importance and management","author":"IH Stockley","year":"1999","unstructured":"Stockley IH (1999) Drug interactions: a source book of adverse interactions, their mechanisms, clinical importance and management. Pharmaceutical Press, London"},{"key":"BF03040747_CR15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/clpt.1980.235","volume":"28","author":"E Perucca","year":"1980","unstructured":"Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A (1980) Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 28: 779\u2013789","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"BF03040747_CR16","first-page":"S11","volume":"55","author":"BFD Bourgeois","year":"2000","unstructured":"Bourgeois BFD (2000) Pharmacokinetic properties of current antepileptic drugs: what improvements are needed? Neurology 55 [Suppl 3]: S11-S16","journal-title":"Neurology"},{"key":"BF03040747_CR17","first-page":"3","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"GR Wilkinson","year":"2001","unstructured":"Wilkinson GR (2001) Pharmacokinetics, the dynamics of drug absorption, distribution and elimination. In: Hardman JG, Limbird LE (eds) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 3\u201329","edition":"10th edn."},{"key":"BF03040747_CR18","first-page":"399","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"DS Charney","year":"2001","unstructured":"Charney DS, Mihic J, Harris RA (2001) Hypnotics and sedatives. In: Hardman JG, Limbird LE (eds) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 399\u2013427","edition":"10th edn."},{"key":"BF03040747_CR19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17332","volume":"32","author":"GD Anderson","year":"1998","unstructured":"Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32: 554\u2013563","journal-title":"Ann Pharmacother"},{"key":"BF03040747_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/ebeh.2001.0165","volume":"2","author":"C Smith","year":"2001","unstructured":"Smith C (2001) Drug interactions between psychoactive agents and antiepileptic agents. Epilepsy Behavior 2: 92\u2013105","journal-title":"Epilepsy Behavior"},{"key":"BF03040747_CR21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00002512-200219040-00004","volume":"19","author":"E Spina","year":"2002","unstructured":"Spina E, Scordo MG (2002) Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19: 299\u2013320","journal-title":"Drugs Aging"},{"key":"BF03040747_CR22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00002826-200301000-00008","volume":"26","author":"CW Bazil","year":"2003","unstructured":"Bazil CW, Pedley TA (2003) Clinical pharmacology of antiepileptic drugs. Clin Neuropharmacol 26: 38\u201352","journal-title":"Clin Neuropharmacol"},{"key":"BF03040747_CR23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","volume":"24","author":"TW May","year":"2002","unstructured":"May TW, Rambeck B, J\u00fcrgens U (2002) Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 24: 366\u2013374","journal-title":"Ther Drug Monit"},{"key":"BF03040747_CR24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1528-1157.2002.37701.x","volume":"43","author":"DJ Berry","year":"2002","unstructured":"Berry DJ, Besag FM, Pool F, Natarajan J, Doose D (2002) Lack of an effect of topiramate on lamotrigine serum concentrations. Epilepsia 43: 818\u2013823","journal-title":"Epilepsia"},{"key":"BF03040747_CR25","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/00007691-200012000-00003","volume":"22","author":"RG Morris","year":"2000","unstructured":"Morris RG, Black AB, Lam E, Wesley IS (2000) Clinical study of lamotrigin and valproic acid in patients with epilepsy: using a drug interaction to advantage? Ther Drug Monit 22: 656\u2013660","journal-title":"Ther Drug Monit"},{"key":"BF03040747_CR26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/clpt.1981.66","volume":"29","author":"IM Kapetanovic","year":"1981","unstructured":"Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Perry JK (1981) Mechanism of valproatephenobarbital interaction in epileptic patients. Clin Pharmacol Ther 29: 480\u2013486","journal-title":"Clin Pharmacol Ther"},{"key":"BF03040747_CR27","first-page":"43","volume":"2","author":"B Rambeck","year":"1998","unstructured":"Rambeck B (1998) Antiepileptic drug interactions in polytherapy. Epileptologia 2: 43\u201353","journal-title":"Epileptologia"},{"key":"BF03040747_CR28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1212\/01.WNL.0000076485.09353.7A","volume":"26","author":"A Sabers","year":"2003","unstructured":"Sabers A, Ohman I, Christensen J, Tomson T (2003) Oral contraceptives reduce lamotrigin plasma levels. Neurology 26: 570\u2013571","journal-title":"Neurology"},{"key":"BF03040747_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/15622970309167906","volume":"4","author":"M Mula","year":"2003","unstructured":"Mula M, Trimble MR (2003) Pharmacokinetic interaction between antiepileptic and antidepressant drugs. World J Biol Psychiatry 4: 21\u201324","journal-title":"World J Biol Psychiatry"},{"key":"BF03040747_CR30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1059-1311(98)80074-5","volume":"7","author":"KR Kaufman","year":"1998","unstructured":"Kaufman KR, Gerner R (1998) Lamotrigin toxicity secondary to sertraline. Seizure 7: 163\u2013165","journal-title":"Seizure"},{"key":"BF03040747_CR31","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1097\/00001756-200111160-00037","volume":"12","author":"H Potschka","year":"2001","unstructured":"Potschka H, Fedrowitz M, L\u00f6scher W (2001) P-glycoprotein and multidrug-resistance associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepin in the brain. Neuroreport 12: 3557\u20133560","journal-title":"Neuroreport"},{"key":"BF03040747_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","volume":"36","author":"DM Tishler","year":"1995","unstructured":"Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Anett GM, Raffel C (1995) MDRI gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36: 1\u20136","journal-title":"Epilepsia"},{"key":"BF03040747_CR33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/brain\/awf002","volume":"125","author":"SM Sisodiya","year":"2002","unstructured":"Sisodiya SM, Lin W-R, Harding BN, Squirer MV, Thom M (2002) Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125: 22\u201331","journal-title":"Brain"},{"key":"BF03040747_CR34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/jpet.103.054197","volume":"307","author":"J Weiss","year":"2003","unstructured":"Weiss J, Kerpen CJ, Lindenmaier H, Dormann SMG, Haefeli WE (2003) Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 307: 262\u2013267","journal-title":"J Pharmacol Exp Ther"},{"key":"BF03040747_CR35","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1176\/ajp.141.12.1604","volume":"141","author":"S Shukla","year":"1984","unstructured":"Shukla S, Godwin CD, Long LEB, Miller MG (1984) Lithium-carbamazepin neurotoxicity and risk factors. Am J Psychiatry 141: 1604\u20131605","journal-title":"Am J Psychiatry"},{"key":"BF03040747_CR36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0163-7258(95)00021-6","volume":"67","author":"MC Walker","year":"1995","unstructured":"Walker MC, Patsalos PN (1995) Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 67: 351\u2013384","journal-title":"Pharmacol Ther"},{"key":"BF03040747_CR37","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1517\/14656566.4.11.2079","volume":"4","author":"E Ben-Menachem","year":"2003","unstructured":"Ben-Menachem E (2003) Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother 4: 2079\u20132088","journal-title":"Expert Opin Pharmacother"}],"container-title":["Wiener Klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03040747.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03040747\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03040747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T01:05:07Z","timestamp":1558573507000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03040747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["BF03040747"],"URL":"https:\/\/doi.org\/10.1007\/bf03040747","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}